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Foot-and-mouth  disease  (FMD)  virus  serotype  O is  the most  common  cause  of  FMD  outbreaks  in  India  and
three  of the  six  lineages  that have  been  described  are  most  frequently  detected,  namely  Ind2001,  PanAsia
and  PanAsia  2. We  report  the full  capsid  sequence  of 21  serotype  O viruses  isolated  from  India  between
2002  and  2012.  All  these  viruses  belong  to the  Middle  East–South  Asia  (ME–SA)  topotype.  The  serological
cross-reactivity  of a bovine  post-vaccination  serum  pool  raised  against  the  current  Indian  vaccine  strain,
O/IND/R2/75,was  tested  by  virus neutralisation  test  with  the  23 Indian  ﬁeld  isolates,  revealing  a good
match  between  the  vaccine  and  the  ﬁeld  isolates.  The  cross  reactivity  of the  O/IND/R2/75  vaccine  withMD  virus
ntigenic variation
apsid sequence
pitopes
olyclonal antibodies
19 ﬁeld  isolates  from  other  countries  (mainly  from  Asia  and  Africa)  revealed  a good  match  to 79%  of
the  viruses  indicating  that  the  vaccine  strain  is  broadly  cross-reactive  and could be  used  to  control  FMD
in  other  countries.  Comparison  of  the  capsid  sequences  of  the  serologically  non-matching  isolates  with
the vaccine  strain  sequence  identiﬁed  substitutions  in  neutralising  antigenic  sites  1 and  2,  which  could
explain  the  observed  serological  differences.
© 2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Foot-and-mouth disease (FMD) remains a globally important
ivestock disease affecting cloven-hoofed animals. It is enzootic in
any regions, especially in developing countries where it imposes
 trade barrier upon livestock and their products. The causative
gent, FMD  virus (FMDV) has a rapid mutation rate and exists
n seven immunologically distinct serotypes, O, A, C, Asia 1, SAT
Southern African Territories) 1, 2 and 3, each with a spectrum of
ntigenically distinct strains.
FMDV is a single-stranded, positive-sense RNA virus (Genus
phthovirus, family Picornaviridae).  The viral genome is about
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264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
8.3 kb long, enclosed within a protein capsid. The capsid is
composed of 60 copies each of four different structural proteins
(VP1–4); VP1–3 are surface exposed while VP4 is internal. Crys-
tallographic studies have identiﬁed the structure of the FMDV
capsid [1–4] and immunological epitopes have been mostly found
on surface-oriented interconnecting loops between structural ele-
ments. Studies employing monoclonal antibodies (mAb) have
identiﬁed antigenic sites by sequencing mAb  neutralisation resis-
tant (mar) mutants [5–10]. Of the ﬁve antigenic sites reported so
far for the most extensively studied serotype O, site-1 (G-H loop) is
linear and trypsin-sensitive whereas the others are conformational
and trypsin-resistant.
Serotype O virus is present in all continents where FMD  is
reported, and is antigenically less diverse [11] often exhibiting good
cross-protection between strains. India has a large population of
FMD-susceptible livestock (approximately 528 million) and FMD
is endemic, although starting to be brought under control [12]. In
the Indian sub-continent three FMDV serotypes (O, A and Asia1)
are currently circulating [13], the majority of the outbreaks (∼80%)
being caused by serotype O virus [13–15]. Two  serotype O vac-
cine strains (v/s), O/TNN 24/84 and O/IND/R2/75 were incorporated
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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n the vaccine used for regular vaccination purposes in India until
ctober 2003 when the use of O/TNN/24/84 v/s was  discontinued
16]. Currently only O/IND/R2/75 is being used for vaccination pur-
oses throughout the country to control serotype O outbreaks. In
his study we report the suitability of the O/IND/R2/75 v/s for use
n the country and also provide evidence that this vaccine could
rovide protection against isolates from other countries. In addi-
ion, for the ﬁrst time, we present detailed analysis of the full capsid
equence data of contemporary serotype O Indian isolates.
. Materials and methods
.1. Cells and viruses
Twenty-six serotype O viruses from the Indian sub-continent
ere used in this study (Supplementary Table 1A). One is the cur-
ent v/s O/IND/R2/75 originally isolated from India in 1975; the
ther twenty ﬁve viruses were isolated over an eleven year period,
002 to 2012. These samples were derived from bovine epithelial
issues except one each of caprine and porcine origin. In addition,
9 serotype O viruses submitted to the Food and Agriculture Orga-
isation’s World Reference Laboratory for FMD  (WRLFMD) at the
irbright Institute were also used in this study (Supplementary
able 1B). Two are the v/s O1/BFS and O1/Manisa that were origi-
ally isolated in the UK and Turkey in1967and 1969 respectively;
he 17 other viruses were isolated over an eleven year period (2001
o 2011). These viruses were from three continents; Asia (n = 13),
urope (n = 2) and East Africa (n = 4) (Supplementary Table 1B).
hese samples were mostly derived from bovine epithelial tissues
xcept three of porcine origin and one of caprine origin. All the
iruses were initially grown in primary bovine thyroid cells with
ubsequent passage in either BHK-21 or IB-RS2 cells. Stocks of virus
ere prepared by infecting IB-RS2 cell monolayers and were stored
s clariﬁed tissue culture harvest at −70 ◦C until required.
.2. Polyclonal serum
Antisera were prepared against FMDV O Indian v/s O/IND/R2/75
y immunising ﬁve male calves of 12–15 months old with inactiv-
ted, puriﬁed 146S FMD  virus particles in ISA-206 adjuvant (SEPIC,
rance). Bulk blood was collected on 21 day post-vaccination for
reparation of sera. A pool of equal amounts of sera from these ﬁve
nimals was used in the serological tests. The pooled antiserum
xhibited a homologous titre of log10 2.48 by virus neutralisation
est (VNT).
.3. Two-dimensional micro neutralisation assay (2D-VNT)
The 2D-VNT was carried out using the 21-day post-vaccination
erum pool following established methodology [17]. Antibody
itres were calculated from regression data as the log10 reciprocal
ntibody dilution required for 50% neutralisation of 100 tissue cul-
ure infective units of virus (log10SN50/100 TCID50). The antigenic
elationship of viruses based on their neutralisation by antibodies
s given by the ratio: ‘r1’ = neutralising antibody titre against the
eterologous virus/neutralising antibody titre against the homolo-
ous virus. Differences in the r1-values obtained by the polyclonal
ntiserum were evaluated according to standard criteria [18]. All
he tests were carried out in duplicates and repeated at least twice
nd the average of the two tests was used in further analysis.
.4. Nucleotide (nt) sequencing and analysis of the sequence dataThe sequences of the entire capsid coding region (P1) of
elected Indian type O viruses (n = 21) were generated in this
tudy. RNA extraction from the cell culture grown viruses ande 33 (2015) 693–700
reverse transcription (RT) were performed as described [19]. PCR
was carried out using the “KOD hot-start DNA polymerase” kit
(Novagen) as recommended by the manufacturer, using the for-
ward primer L463F (5′-ACCTCCRACGGGTGGTACGC-3′) and one of
the reverse primers NK72 (5′-GAAGGGCCCAGGGTTGGACTC-3′) or
EUR2B52R (5′-GACATGTCCTCCTGCATCTGGTTGAT-3′). PCR prod-
ucts were puriﬁed using the QIAquick PCR puriﬁcation kit (Qiagen)
according to the manufacturer’s instructions and sequenced using
BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosys-
tems, Carlsbad, CA, USA) using the PCR primers and additional
internal sequencing primers (sequences available on request).
Sequences (from the ABI 3730 machine) were assembled and
analysed using SeqMan II (DNAStar Lasergene 8.0). Nucleotide
sequences of the viruses were aligned using the CLUSTAL X mul-
tiple sequence alignment programme [20] and the predicted aa
sequences were translated using BioEdit 7.0.1 [21]. In addition to
the 21 sequences generated in this study, another ﬁve sequences
(Supplementary Table 1A) available in Gene Bank were also used
in the analysis. Out of these ﬁve capsid sequences O/TNN/24/84,
which was  one of the old Indian serotype O v/s contained the
sequence of only VP1–3 (Acess. no. JQ818555). Therefore sequences
of VP1–3 of all the isolates used in this study were aligned and
used in all subsequent analysis in this study. Alignments were
used to construct distance matrices using the Kimura 2-parameter
nucleotide substitution model [22] as implemented in the pro-
gramme  MEGA 5.1 [23].
2.5. Bayesian phylogenetic analysis
The VP1–3 sequences of the viruses belonging to the Indian
serotype O strain (n = 26) were aligned and subjected to jModelTest
0.1.1 [24]. The general time reversible (GTR) model for nucleotide
substitution was  used with a combination of gamma  distribution
and proportion of invariant sites (GTR + I + G) as this was  found to
be the best model for the Bayesian analysis of the sequence dataset.
Analysis was  performed using the BEAST software package v 1.5.4
[25] with the maximum clade credibility (MCC) phylogenetic tree
inferred from the Bayesian Markov Chain Monte Carlo (MCMC)
method. The age of the viruses were deﬁned by the date of sam-
ple collection. In BEAUti v1.5.4, the analysis utilised the GTR  + I + G
model to describe rate heterogeneity among sites. In order to
accommodate variation in substitution rate among branches, a ran-
dom local clock model was  chosen for this analysis [26]. BEAST
output was  viewed with TRACER 1.5 and evolutionary trees were
generated in the FigTree program v1.3.1.
2.6. Data analysis
The proportion of synonymous substitutions per potential syn-
onymous site and the proportion of non-synonymous substitutions
per potential non-synonymous site were calculated by the method
of [27] using the SNAP programme (www.hiv.lanl.gov). The amino
acid (aa) variability of the capsid region of the serotype O viruses
was determined as described by [28]. Statistical analyses used
Minitab release 12.21 software.
3. Results and discussion
The population of FMD-susceptible livestock in India is very
large. The Government of India is undertaking an FMD  control pro-
gramme  (FMDCP) and in their last (10th) ﬁve-year plan covered
54 districts in several states [12,29,30]. There were 16 rounds of
vaccination in these 54 districts using an inactivated trivalent vac-
cine containing strains of serotype O, A and Asia 1. Even though the
programme was  successful in reducing the incidence of FMD, the
disease still occurred due to movement of animals and the existence
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ine  indicates the cut-off value of 0.3, above which the vaccine is considered to be a
f areas not covered under the control programme. In the 11th
lan (started Oct 2010), an additional 167 districts were included
nd currently a total of 221 districts are targeted involving about
8% of the total cattle, buffalo and pig population in the country. In
he next ﬁve-year plan (starting in 2015) the control programme
s likely to include the entire country. The effectiveness of the con-
rol programme relies heavily on an efﬁcacious and safe vaccine,
hich in the case of FMD  requires that the vaccine strain can pro-
ect against the outbreak strains. Out of the three serotypes (O, A
nd Asia 1) prevalent in India, serotype O causes most of the out-
reaks. Currently, three different lineages of serotype O viruses,
amely Ind2001, PanAsia and Ind2011 are circulating in India [30].
.1. Serological characterisation of the Indian serotype O viruses
ith O/IND/R2/75 sera
The cross-reactivity of the Indian serotype O viruses (n = 23) was
easured by 2D-VNT using a pool of O/IND/R2/75 post-vaccination
ovine sera. All the viruses exhibited strong cross-reactivity with
he antisera indicating that the current v/s is a good match for the
urrently circulating ﬁeld isolates (Fig. 1A). This indicates that the
urrent Indian serotype O vaccine strain has a broad serological
pectrum similar to an earlier report [16]. However two  isolates,
/ORC/20/2003 and O/APV/93/2004 exhibited an r1-value less than
.4 (0.33 and 0.38, respectively). Therefore continuous monitor-
ng of the outbreak strains and regular vaccine matching studies
s essential to evaluate the suitability of the vaccine for use in
he control programme in the country unless poor match can be
ompensated for by high antigen payload vaccines [31].
.2. Serological cross-reaction between recent ﬁeld isolates from
ther countries and the Indian type O vaccine strain
The cross-reactivity of some recent serotype O viruses from
ther countries was measured by 2D-VNT using the O/IND/R2/75
ost-vaccination serum pool. About 79% of the viruses (15/19)
eacted well with the antisera including viruses representing
he MYA-98 strain (SEA topotype) and the EA-2 and EA-
 strains (AFRICA topotype). This indicates that the current
ndian v/s is broadly cross reactive and might provide pro-
ection if used as a vaccine to control outbreaks in other
ountries (Fig. 1B). Four isolates, O/HKN/03/2004, O/UAE/04/2009,
/IRN/08/2010 and O/PAK/20/2010 exhibited an r1-value lower
han 0.3. O/HKN/03/2004 belongs to the Cathay topotype with verym other countries (B) against O/IND R2/75 vaccine antisera. The horizontal dotted
 match.
distinct host speciﬁcity, mainly affecting pigs [32]. O/PAK/20/2010
(PUN-10 sub-lineage) and O/IRN/08/2010 (FAR-09 sub-lineage)
belong to the PanAsia-2 lineage within ME-SA topotype. It was
surprising that O/UAE/04/2009 belonging to the Ind2001 lineage
within ME-SA topotype was not a good match whilst the Indian
serotype O isolates from the same lineage exhibited high r1-values.
This virus has a three nucleotide deletion in the G–H loop region at
position VP1-139, similar to the report of Das and colleagues [13].
3.3. Genetic characterisation of the serotype O viruses
3.3.1. Full capsid sequence analysis
The full capsid sequences of the selected Indian viruses (n = 21)
were generated in this study and the viral capsid sequences were
assembled using DNASTAR Lasergene 10 EN. All the sequences were
2202 nt long except O/TNKr/58/2007 which had a 3-nt deletion at
position 1978–1980 of P1 leading to the deletion of an aa at position
137 of the VP1 in the G–H loop which has been reported to be a dom-
inant antigenic site (Site 1). Interestingly, an amino acid deletion at
VP1-139 position has been reported previously in outbreak viruses
belonging to the same lineage (Ind2001) from Gujarat state isolated
in 2009 [13]. Compared to the oldest virus O5/IND/1962, the varia-
tion at nt level was 8.2% (O/GUK/143/2002) to 11.2% (O/TNN/24/84)
and 2% (O/GUK/143/2002) to 5.2% (O/IND/75Madras) at aa level.
Similarly, compared to the vaccine strain O/IND/R2/75, the varia-
tion was  3.7% (O/IND/75Madras) to 12.12% (O/KEKM/06/2009) at
nt level and 3.7% (O/GUK/143/2002 and O/MPSH/09/2005) to 5.5%
(O/IND/75Madras) at aa level. The sequence dataset was analysed
by the Z-test for evidence of evolutionary selection using MEGA 5.1,
but this was not found (P > 0.1) which probably explains why the
vaccine still works on the recent isolates.
3.3.2. Phylogenetic analysis
Phylogenetic analysis of the capsid sequences revealed that all
of the Indian serotype O viruses belong to the ME-SA topotype.
The Indian viruses isolated from 2002 onwards clustered together,
whereas the other virus strains did not (Fig. 2). A similar pattern
was observed when phylogenetic trees were drawn using only VP1
sequences (data not shown).3.3.3. Rate of nucleotide substitution per site
From the BEAST analysis, using a random local molecular clock,
the rate of substitution of all the nt changes in the capsid cod-
ing region of the serotype O viruses from India was estimated to
696 M. Mahapatra et al. / Vaccine 33 (2015) 693–700
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e 1.78 × 10−3/site/year (95% HPD 1.23 × 10−3 to 2.41 × 10−3). This
s similar to the report of Hemadri and colleagues [14] for Indian
erotype O FMD  viruses and also by others in case of serotype O FMD
iruses [33–36], however, it is lower than that of Indian serotype
 viruses of the Ind2001 lineage reported by Subramaniam and
olleagues [30]. The common ancestor of these viruses could have
xisted about 83.9 years ago, i.e. 1928 (95% HPD 67.1 to 102.48
ears).
.3.4. Serotype O Indian viruses
An unbiased analysis of the capsid sequences (VP1–3) of the
6 Indian serotype O viruses revealed 786 nt substitutions at 636
ites distributed across the region (Fig. 3A). Out of these, 80.05% of
t substitutions were found to be synonymous (silent) and 19.95%
ere non-synonymous (non-silent). Twenty three sites were iden-
iﬁed to have been substituted three times and 104 sites were
ubstituted twice. At eight sites, all the three bases of the codon
able 1A
apsid positions where multiple amino acid substitutions were observed. The changes ar
Viral protein Positions with three
amino acid
substitutions
Position
amino a
substitu
VP2 39 (A -> S/V/T) – 
VP1  96 (T -> N, A, K), 137 (A -> G/S/V), 144 (V -> I/K/L) 133 (N (n = 5) retrieved from Genbank are indicated by their respective accession numbers.
were mutated encoding 3–6 different aa (Table 1A). Out of the eight
sites with three nt substitutions (encoding 3–6 aa residues), two
were present in VP2 and six in VP1 (Table 1A).
The analysis of the capsid aa residues of O Indian viruses
revealed 157 substitutions at 104 sites across the capsid (Fig. 3A)
with some sites having 2–7 alternative aa (Table 1A). Interestingly,
sequences for VP2-133 and VP1-138 encoded seven different aa and
exhibited nt changes at all the three positions within the codon as
did VP1-140 and VP1-133,with changes at all the three positions
of the codon giving rise to six and ﬁve alternative aa, respectively.
The non-synonymous nt substitutions were not equally distributed
across the capsid coding regions: there were several local areas
where the dN/dS ratio was higher than in other parts of the
sequence alignment (Fig. 3B). Two regions in VP3 (53 and 69–73),
one region in VP2 (131–133) and four regions in VP1 (127–140,
171–174, 194–197 and 208–209) had dN/dS ratio of >0.7, indicative
of sites under positive selection. Out of these regions the residues in
e shown in parenthesis.
s with four
cid
tions
Positions with ﬁve
amino acid
substitutions
Positions with six
amino acid
substitutions
– 133 (Q -> D/G/S/H/N/T)
-> D/G/S/A) 140 (P -> D/G/S/A/T) 138 (D -> E/R/A/K/N/G)
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P1 127–140 had the highest dN/dS ratio (>1.5) indicating strongest
election pressure in case of serotype O viruses.
.3.5. Amino acid variability of the capsid of the Indian serotype
 viruses
Investigation of aa variability across the capsid of the Indian
erotype O viruses revealed VP4 to be highly conserved (data not
hown) and VP1 least conserved (Fig. 4A); similar to an earlier
eport of serotype A viruses [37]. The residues with a variability
core greater than 0.3 (one each in VP2 and VP3, and 6 in VP1) are
hown in Fig. 4B–C indicating that 75% of the residues with high
ariability scores were present in VP1 (Fig. 4A). All these residues
ere found to be surface-exposed (Fig. 4C).
.4. Correlating genotype to antigenic phenotype
In an attempt to correlate genotype to antigenic phenotype, the
apsid aa sequences of the serotype O viruses employed in this
tudy were further analysed. A number of amino acid changes were
bserved between the v/s and the ﬁeld isolates. However there
as no linear correlation between the number of aa substitutions black line indicates total cumulative nucleotide changes, the grey line—cumulative
otted line indicates gene junctions.
and the loss of serological cross-reactivity (data not shown) as the
isolates displaying an equal no. of aa differences exhibited sig-
niﬁcantly different serological cross-reactivity indicating a large
proportion of the substitutions are neutral and only a few located
at particular position of the capsid have an impact on the antigenic
phenotype of the virus [37–39].
3.5. Comparison between O/IND/R2/75 v/s and the serologically
non-matching ﬁeld isolates
In-vitro testing of four serotype O viruses (O/HKN/03/2004,
O/UAE/04/2009, O/IRN/08/2010 and O/PAK/20/2010) with
O/IND/R2/75 antisera generated r1-values lower than 0.3 indi-
cating lower expectation of protection efﬁciency. In addition
two of the Indian serotype O viruses, namely O/ORC/20/2003
and O/APV/93/2004 also exhibited comparatively lower cross-
reactivity with the O/IND/R2/75 antisera (r1-values <0.4). The
capsid aa sequences of these six viruses were aligned with the v/s
sequence and analysed further to investigate the molecular basis
of the lower cross-reactivity of these viruses with O/IND/R2/75
vaccine strain. As most of these viruses (six isolates) exhibited
698 M. Mahapatra et al. / Vaccine 33 (2015) 693–700
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1FOD, reduced) with highly variable capsid amino acid residues (with a score of
xternal surface. (For interpretation of the references to color in this ﬁgure legend, 
ower cross-reactivity with the antisera of the v/s, we speciﬁcally
ooked for amino acid residues in the ﬁeld isolates which were
ifferent from the v/s. A total of 16 capsid amino acid residues;
ve in VP2, six in VP3 and ﬁve in VP1 (Table 1B, Fig. 5) were
dentiﬁed which may  have an impact on the antigenic nature of
he viruses. Three of these residues were eliminated as being com-
letely buried (VP2-154, VP3-86 and VP1-123) in the structure.
n addition, VP1-82 which is located close to the ﬁve-fold axis is
ess accessible to antibody binding and was therefore excluded.
he remaining 12 residues were surface exposed (Fig. 5B) and are
herefore good candidates to explain the inability of the antisera
o cross-react with the ﬁeld isolates. Three of the residues; VP2-70
nd 134 involving antigenic site 2 and VP1-144 involving antigenic
ite 1 have been reported to be critical in serotype O mar-mutant
tudies [7,40]. Neutralising antigenic site 2 has been reported to
able 1B
mino acid changes between O/IND/R2/75 v/s and serologically non-matching ﬁeld
solates. Numbers where shown in parenthesis indicates no. of isolates with the sub-
titution over total no. of isolates. At all othere positions the changes were observed
n  all the six serologically non-matching isolates.
VP2 VP3 VP1
Position Change Position Change Position Change
70 A–V/G 56 R–H 82 Y–H
74  S–P (4/6) 60 G–D 96 N–T
134  N–E/K 86 I–M 123 Q–H
154  V–M 96 H–Q 139 G–S/T
191  T–N/S (5/6) 219 R–T 144 I–V
220 D–Qotted line indicates gene junctions. (B–C) 3-D structure of O BFS reduced protomer
 than 0.3) highlighted.VP1 residues—blue, VP3—red, VP2—green; (B) cartoon, (C)
ader is referred to the web  version of this article.)
be immunodominant in the polyclonal response of serotype O
FMD-vaccinated animals followed by site 1 [41]. VP2-134 has also
been reported to strongly inﬂuence the binding of neutralising
antigenic site 2 mAbs in serotype O FMDV [19]. In addition VP2-74
and 191 have been recently shown to be linked to antigenic site
2 using a reverse genetics approach [39]. The S–P substitution
at position 74 of VP2 could be signiﬁcant as proline is known
to be a helix-breaker. Though never reported to be a part of an
epitope in any serotypes of FMDV, the residue VP3-219 and 220
are in close vicinity to residue VP3-218, which has been recently
reported to be critical in serotype Asia 1 [10]. In addition, VP3-220
had been indicated to have an impact on the antigenic nature of
serotype A FMD  viruses [37]. Three residues in VP3 (96, 219 and
220) and one residue in VP1 (96) are located next to each other
(Fig. 5B) and also in close proximity to the C-terminus of VP1 of
an adjacent protomer; therefore potentially could form or be part
of an epitope. A change in these residues may  affect the overall
conformation of the viral capsid and thereby alter the antigenicity
of the virus.
In summary, the current Indian serotype O vaccine strain
O/IND/R2/75 is a good match with the circulating ﬁeld isolates
in India and with the majority of the ﬁeld isolates studied from
other, mainly Asian countries (except Cathay topotype viruses)
and East Africa. This indicates that O/IND/R2/75 is broadly cross-
reactive and, therefore could be used as a vaccine to control the
disease in other endemic countries. However, comparatively lower
cross-reactivity of the O/IND/R2/75 BVS with two  of the Indian
serotype O isolates and an isolate from United Arab Emirates that
belong to Ind2001 lineage indicates that the antigenic phenotype
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